PLAT and androgen insensitivity syndrome: AIS affects over 15 million patients yearly worldwide, and represents the fifth-leading cause of death and leading cause of disability in the United States.1 Currently, the only FDA-approved medical therapy for treatment of AIS is thrombolysis with recombinant tissue plasminogen activator (tPA) within three hours of symptom onset.